George Chidi, a politics and democracy reporter for Guardian US, recently visited Europe for a vacation. He anticipated indulging in delicious food in Paris and London, particularly looking forward to the cheese. Surprisingly, he found he wasn’t overeating despite enjoying the cuisine. Chidi revealed to Hannah Moore that he had been using the weight-loss medication Ozempic for a few months. Although nearly 2% of the US population is taking it, the company that produces it is worth billions. The rise of semaglutide weight-loss drugs like Ozempic has only just begun to impact society.
The effects range from reduced profits for fast-food chains to potential breakthroughs in treating various diseases. However, Chidi, who often covers inequality in his reports, raised concerns about the drug’s affordability and how it might exacerbate social disparities. While these medications could enhance national health, they may inadvertently deepen societal divisions.
Support The Guardian
The Guardian is committed to editorial independence, striving to keep journalism open and accessible. Your support is crucial in sustaining our work. Support The Guardian